Search Result

Results for "

Anti-tumor peptide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (2) Peptide-Drug Conjugates (PDCs) (3) ADC Cytotoxin (1) ADC Linker (1) Akt (1) Amino Acid Derivatives (2) Aminopeptidase (2) Antibiotic (4) Apoptosis (22) Autophagy (2) Bacterial (16) Bcl-2 Family (3) Beta-lactamase (1) Biochemical Assay Reagents (4) Caspase (2) CD47 (1) DNA/RNA Synthesis (1) Drug-Linker Conjugates for ADC (1) EGFR (2) ERK (1) FAP (2) FGFR (1) Folate Receptor (FR) (1) Fungal (10) Histone Methyltransferase (1) HPV (3) Integrin (1) Interleukin Related (2) Liposome (3) MDM-2/p53 (4) MEK (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) MMP (2) Necroptosis (1) Neurokinin Receptor (1) PARP (2) PD-1/PD-L1 (5) PI3K (1) Pim (1) PKC (2) Protein Arginine Deiminase (1) Raf (1) Ras (3) Reactive Oxygen Species (2) ROR (1) STAT (1) Thrombopoietin Receptor (1) Toll-like Receptor (TLR) (1) Topoisomerase (2) TRP Channel (1) VEGFR (2) YAP (2)
By Research Areas:	Cancer (80) Cardiovascular Disease (1) Endocrinology (1) Infection (17) Inflammation/Immunology (9) Metabolic Disease (1) Neurological Disease (1)

By Targets:

Amyloid-β (2)

Peptide-Drug Conjugates (PDCs) (3)

ADC Cytotoxin (1)

ADC Linker (1)

Akt (1)

Amino Acid Derivatives (2)

Aminopeptidase (2)

Antibiotic (4)

Apoptosis (22)

Autophagy (2)

Bacterial (16)

Bcl-2 Family (3)

Beta-lactamase (1)

Biochemical Assay Reagents (4)

Caspase (2)

CD47 (1)

DNA/RNA Synthesis (1)

Drug-Linker Conjugates for ADC (1)

EGFR (2)

ERK (1)

FAP (2)

FGFR (1)

Folate Receptor (FR) (1)

Fungal (10)

Histone Methyltransferase (1)

HPV (3)

Integrin (1)

Interleukin Related (2)

Liposome (3)

MDM-2/p53 (4)

MEK (1)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

MMP (2)

Necroptosis (1)

Neurokinin Receptor (1)

PARP (2)

PD-1/PD-L1 (5)

PI3K (1)

Pim (1)

PKC (2)

Protein Arginine Deiminase (1)

Raf (1)

Ras (3)

Reactive Oxygen Species (2)

ROR (1)

STAT (1)

Thrombopoietin Receptor (1)

Toll-like Receptor (TLR) (1)

Topoisomerase (2)

TRP Channel (1)

VEGFR (2)

YAP (2)

By Research Areas:

Cancer (80)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (17)

Inflammation/Immunology (9)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Targets Recommended: Formyl Peptide Receptor (FPR) Peptide-Drug Conjugates (PDCs) Natriuretic Peptide Receptor (NPR) TNF Receptor RXFP Receptor BRK CGRP Receptor Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10420

RS17	CD47 Interleukin Related	Cancer
RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape .

HY-P3586

HKPao Hunter-killer peptide ao; Prohibitin-targeting peptide 1; prohibitin-TP01; Adipotide	Apoptosis	Cancer
HKPao (Hunter-killer peptide ao) is a biologically active peptide. HKPao (Hunter-killer peptide ao) has anti-obesity and anti-tumor pro-apoptotic activity to cause release of cytochrome c from vesicles .

HY-122097

M7594_0037	Others	Cancer
M7594_0037 is a potent inhibitor of human peptide deformylase (HsPDF) that has anti-tumor activity .

HY-P3707

**Tumor targeted pro-apoptotic peptide**	Apoptosis	Cancer
Tumor targeted pro-apoptotic peptide (CNGRC-GG-D(KLAKLAK)2) is an anti-tumor peptide. Tumor targeted pro-apoptotic peptide disrupts mitochondrial membranes and promotes apoptosis, showing anticancer activity in mice .

HY-P2299

Protein E7(43-62)	HPV	Cancer
Protein E7(43-62) is an E7-derived peptide with anti-tumor effects (short peptide spanning the 43th to 62th amino acid residues in the E7 protein) .

HY-P5020

Crotalicidin	Bacterial	Infection Cancer
Crotalicidin is an antimicrobial peptide and anti-tumor peptide that can effectively inhibit the activity of Gram-negative bacteria and tumor cells. Crotalicidin can be obtained from rattlesnake venom. Crotalicidin can be used in the study of microbial infections and cancer .

HY-P2299A

Protein E7(43-62) TFA	HPV	Cancer
Protein E7(43-62) TFA is an E7-derived peptide with anti-tumor effects (short peptide spanning the 43th to 62th amino acid residues in the E7 protein) .

HY-P10832

ATWLPPRAANLLMAAS	Apoptosis Ras Raf MEK ERK Caspase PARP Bcl-2 Family	Cancer
ATWLPPRAANLLMAAS is a chimeric peptide with anti-angiogenic and potent anti-tumor effects. ATWLPPRAANLLMAAS can inhibit the proliferation, viability, migration, and invasion of human hepatocellular carcinoma cells, and induce apoptosis. .

HY-P10550

VGB4	VEGFR	Cancer
VGB4 is a VEGF-A and VEGF-B antagonist peptide that duplicates two binding domains of VEGF-B (loop 1 and loop3) and are linked together by the receptor-binding domain of VEGF-A (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research .

HY-P1404

R8-T198wt	Pim	Cancer
R8-T198wt is a cell-permeable carboxyl-terminal p27 ^Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase .

HY-P2268

RAGE antagonist peptide 2 Publications Verification	Amyloid-β	Inflammation/Immunology Cancer
RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities .

HY-P2268A

RAGE antagonist peptide TFA 2 Publications Verification	Amyloid-β	Inflammation/Immunology Cancer
RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities .

HY-P10285

d-KLA Peptide D-(KLAKLAK)2	Mitochondrial Metabolism PARP Caspase	Cancer
d-KLA Peptide is a synthetic pro-apoptotic peptide. d-KLA Peptide can specifically target mitochondria and induce apoptosis by destroying the mitochondrial membrane. d-KLA Peptide activates biochemical pathways associated with apoptosis, including the activation of caspase family proteins and PARP (poly ADP ribose polymerase). d-KLA Peptide can be used to carry and deliver genes or small molecules to enhance anti-tumor effects .

HY-P1728

Super-TDU (1-31)	YAP	Cancer
Super-TDU (1-31) is a peptide fragment of Super-TDU. Super-TDU (1-31) is an inhibitor of YAP-TEAD complex. Super-TDU shows potent anti-tumor activity and suppresses tumor growth in gastric cancer mouse model .

HY-P1728A

Super-TDU (1-31) TFA	YAP	Cancer
Super-TDU (1-31) TFA is a peptide fragment of Super-TDU. Super-TDU (1-31) TFA is an inhibitor of YAP-TEAD complex. Super-TDU TFA shows potent anti-tumor activity and suppresses tumor growth in gastric cancer mouse model .

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Amino Acid Derivatives	Others Cancer
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

HY-155801

CRX 527	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
CRX 527 is a ligand of TLR4 and also serves as an adjuvant for peptide-based cancer vaccines, showing potential to enhance anti-tumor immune responses. CRX 527 can also induce HSC differentiation, increase the proportion and quantity of LSK cells, and promote their differentiation into macrophages, activating immune defense and protecting intestinal epithelium from radiation damage .

HY-P10930A

wrwycr-NH2 TFA	DNA/RNA Synthesis	Cancer
wrwycr-NH2 (TFA) is a peptide. wrwycr-NH2 (TFA) is cytotoxic to multiple cancer cells, can induce DNA damage and cell cycle arrest, but does not induce endoplasmic reticulum stress. wrwycr-NH2 (TFA) has anti-tumor activity, and it shows better efficacy when used in combination with DNA-damaging agents .

HY-122720

SEC inhibitor KL-1 1 Publications Verification KL-1	Apoptosis	Cancer
SEC inhibitor KL-1 (KL-1) is a peptide-like lead compound that is an effective selective SEC inhibitor. SEC inhibitor KL-1 promotes apoptosis and has anti-tumor activity. SEC inhibitor KL-1 doses dependently inhibits the AFF4-CCNT1 interaction, with a Ki value of 3.48 μM .

HY-P10515

AcrAP2	Bacterial Fungal	Infection Cancer
AcrAP2 is an antimicrobial peptide present in the venom of the Arabian scorpion (Androctonus crassicauda). AcrAP2 is inhibitory against Gram-positive bacteria and yeast but is essentially inactive against Gram-negative bacteria. A cation-enhanced AcrAP2 analog (AcrAP2a) exhibits significant antiproliferative effects at low concentrations against certain human cancer cell lines. AcrAP2 can be used in antibacterial and anti-tumor research .

HY-155995

PRO-905 MK-905	Biochemical Assay Reagents	Cancer
Pro-905 is a phosphite peptide with antitumor activity. Pro-905 delivers the active nucleotide antimetabolite thioguanosine monophosphate (TGMP) to the tumor. Pro-905 effectively prevents incorporation of purine salvage substrates into nucleic acids and inhibits colony formation in human malignant peripheral nerve sheath tumors (MPNST) cells. Pro-905 inhibits purine salvage incorporation to nucleic acids and prevents cell growth. Pro-905 inhibits the growth of MPNST and enhances the anti-tumor efficacy of JHU395 (HY-124778) .

HY-P10370

d-(KLAKLAK)2, Proapoptotic Peptide	Bacterial Apoptosis	Infection Cancer
d-(KLAKLAK)2, as an antibacterial and anti-tumor polypeptide, is a representative of the antimicrobial peptide group, and also has good anticancer properties. d-(KLAKLAK)2 is able to kill bacteria by damaging their cell membranes, causing cell contents to leak out. d-(KLAKLAK)2 can also inhibit tumor cell proliferation by causing mitochondrial swelling and mitochondrial membrane destruction, triggering apoptosis (programmed cell death) .

HY-P5557

TP4 (Nile tilapia piscidin)	Bacterial Necroptosis	Cancer
TP4 (Nile tilapia piscidin) is an orally active piscidin-like antimicrobial peptide. TP4 inhibits multiple gram positive and negative strains (MIC: 0.03-10 μg/mL). TP4 shows hemolytic activities. TP4 enhances immune response, antioxidant activity, and intestinal health against bacterial infections. TP4 also has anti-tumor effect, and induces necrosis by triggering mitochondrial dysfunction in cancer cells .

HY-107691

GR 159897	Neurokinin Receptor	Neurological Disease Endocrinology Cancer
GR 159897 is a highly potent, selective, competitive, brain-penetrated non-peptide neurokinin 2 (NK₂) receptor antagonist. GR 159897 has little or no affinity for NK₁ and NK₃ receptors. GR 159897 inhibits binding of [ ³H]GR100679 to human NK₂ (hNK₂)-CHO cells and rat colon membranes with pK_is of 9.51 and 10, respectively. Antagonizes bronchoconstriction. Anxiolytic-like and anti-tumor effects .

HY-P10553

ARF(26–44), cell-permeable	Apoptosis	Cancer
ARF(26–44), cell-permeable is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26–44) cell-permeable shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26–44), cell-permeable can be used in research on tumor therapy .

HY-P2157

Ras Inhibitory Peptide	Ras	Cancer
Ras Inhibitory Peptide (VPPPVPPRRR) is a Ras inhibitor with antitumor activity .

HY-P10709

CREKA peptide	Biochemical Assay Reagents	Cardiovascular Disease Cancer
CREKA peptide is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-119675

Albonoursin	Bacterial	Infection Cancer
Albonoursin, a microbial secondary metabolite, is an antibacterial peptide. Albonoursin displays antibacterial and antitumor activities .

HY-P10610

Peptide 234CM	MDM-2/p53	Cancer
Peptide 234CM is a peptide containing isoleucine at position 3, corresponding to the sequence of a point mutation in p53 codon 234. Peptide 234CM induces potent cytotoxic T cell (CTL) and antitumor immune responses against mutant p53 .

HY-P1828

EGFRvIII peptide (PEPvIII)	EGFR	Cancer
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy .

HY-P1828A

EGFRvIII peptide (PEPvIII) TFA	EGFR	Cancer
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy .

HY-P10128

GE11 1 Publications Verification	Biochemical Assay Reagents	Inflammation/Immunology
GE11 is a active peptide and combines with colloidal drug delivery systems as smart carriers for antitumor drugs and can be used for cancer study .

HY-P5910

Azurin p28 peptide	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .

HY-P10705

KGFRWR	Biochemical Assay Reagents	Cancer
KGFRWR is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. KGFRWR can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-P5910A

Azurin p28 peptide TFA	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide TFA is a tumor-penetrated antitumor peptide. Azurin p28 peptide TFA redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide TFA induces apoptosis or cell cycle arrest. Azurin p28 peptide TFA inhibits p53-positive tumor growths. Azurin p28 peptide TFA shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .

HY-161096

Antitumor agent-127	ROR	Cancer
Antitumor agent-127 (compound 1) is a parent macrocyclic peptide. Antitumor agent-127 displays nanomolar cell-based binding to ROR1 and relatively good internalization in 786-O and MDA-MB-231 tumor cell lines .

HY-P10742

CBX-12	Peptide-Drug Conjugates (PDCs) Topoisomerase	Cancer
CBX-12 is a PDC (peptide drug conjugate) that targets tumors in an antigen-independent manner and exhibits antitumor activity. CBX-12 consists of a pH-sensitive peptide (pHLIP), a self-immolating linker, and a topoisomerase 1 (TOP1) inhibitor Exatecan (HY-13631) .

HY-P2322

Iturin A 1 Publications Verification	Fungal Reactive Oxygen Species Apoptosis Autophagy	Infection Cancer
Iturin A is a cyclic lipid peptide with strong antifungal activity. Iturin A induces ROS explosion and induces apoptosis and autophagy in tumor cells. Iturin A has antitumor activity .

HY-172498

DSPE-PEG5000-CREKA	Liposome	Cancer
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-172497

DSPE-PEG2000-CREKA	Liposome	Cancer
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172496

DSPE-PEG1000-CREKA	Liposome	Cancer
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-147021

MC-Val-D-Cit-PAB-PNP	ADC Linker	Cancer
MC-Val-D-Cit-PAB-PNP is a cleavable peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs). MC-Val-D-Cit-PAB-PNP contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-nitrophenol (PNP) group that allows the peptide to be linked to antitumor compounds.

HY-P3365

Cecropin D	Bacterial	Inflammation/Immunology Cancer
Cecropin D is an antimicrobial peptide with a MIC of 4.55 μg/mL. Cecropin D is effective against both Gram-negative and Gram-positive bacteria. Cecropin D has antiviral, antifungal, antitumor, and immunomodulatory .

HY-P10090

Apoptin-derived peptide	Akt PI3K Apoptosis	Cancer
Apoptin-derived peptide is an antitumor polypeptide with cytotoxicity. Apoptin-derived peptide promotes apoptosis and necrosis of gastric cancer (GC) cells by regulating PI3K/AKT/ARNT signaling. Apoptin-derived peptide inhibited the invasion and migration of cancer cells, and inhibited the expression and phosphorylation of the subunit p85 of PI3K, which further inhibited the PI3K/AKT pathway involved in the development of gastric cancer .

HY-147057

Rofapitide tetraxetan 2 Publications Verification FAP-2286	FAP	Cancer
Rofapitide tetraxetan (FAP-2286) is a potent and selective FAP-binding peptide with a mean IC₅₀ value of 2.7 nM for binding to FAP. Rofapitide tetraxetan can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan has antitumor activity .

HY-147057A

Rofapitide tetraxetan acetate FAP-2286 acetate	FAP	Cancer
Rofapitide tetraxetan (FAP-2286) acetate is a potent and selective FAP-binding peptide with a mean IC₅₀ value of 2.7 nM for binding to FAP. Rofapitide tetraxetan acetate can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan acetate has antitumor activity .

HY-P10826

PD-1/PD-L1 inhibitory peptide C8	PD-1/PD-L1	Cancer
PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .

HY-P10286

Phage-derived 12/1 peptide	MDM-2/p53	Cancer
Phage-derived 12/1 peptide exhibits antitumor activity by targeting MDM2 and MDMX, an thus disrupt the MDM2-p53 and MDMX-p53 interaction, with IC₅₀ of 0.15 and 1.25 μM .

HY-P3732

RGD-4C	Integrin	Cancer
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .

HY-P1791

Lactoferrin (17-41) Lactoferricin B; Lfcin B	Bacterial Fungal Apoptosis	Infection Cancer
Lactoferrin 17-41 (Lactoferricin B), a peptide corresponding to residues 17-41 of bovine lactoferrin, has antimicrobial activity against a wide range of microorganisms, including Gram-positive and Gramnegative bacteria, viruses, protozoa, and fungi. Lactoferrin 17-41 has antitumor activities .

Cat. No.	Product Name

HY-L110

Cyclic Peptide Library

90 compounds

Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs.

MCE offers a unique collection of 90 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

Cat. No.	Product Name	Type